There was an allegation of a discrepant negative elecsys hiv duo result for one patient sample from a cobas e 801 module serial number (b)(6).On (b)(6), 2023, the following results were obtained: the initial result from the hiv duo was 0.852 coi, non-reactive (hivag 0.186 coi and ahiv 0.831 coi).The repeat result from the hiv duo was 0.811 coi, non-reactive (hivag 0.186 coi and ahiv 0.789 coi).The repeat result from the hiv duo on a second e 801 module was 0.925, non-reactive.The result from the hiv combipt on an e 601 module was 1.65 coi, reactive.The result from the alinity hiv ag/ab method was 4.87 s/co, reactive.The result from the architect hiv ag/ab method was 5.08 s/co, reactive.The result from the hiv ab vidas method was 0.52 (cutoff 0.25), reactive.The initial result from the hiv pcr (cobas mpx test) was ct 37.13, reactive and repeated as ct 37.13, reactive.The result from the hiv 1/2 geenius (immunochromatography test) was reactive (gp140 present).On (b)(6), 2023, the following results were obtained from a new sample, collected from the same patient: the result from the hiv duo was 2.09 coi, reactive (hivag 0.173 coi and ahiv 2.08 coi).The result from the alinity hiv ag/ab method was 4.47 s/co, reactive.The result from the hiv pcr (cobas mpx test) method was ct 36.94, reactive.The result from the hiv 1/2 geenius (pcr-immunochromatography test) was reactive (gp140 present).On (b)(6), 2023, the initial sample was repeated on a different cobas e 801 by using reagent lot 631252: the result from the hiv duo was 0.925 coi, non-reactive.On (b)(6), 2023, recalibration was performed and the initial sample was repeated: the result from the hiv duo was 0.829 coi, non-reactive.No questionable results were reported outside of the laboratory.
|
Calibration signals were acceptable.Quality controls were within specifications.Two patient samples were received for investigation and retested.The sample draw from 12-jun-2023 was found to be non-reactive and the sample draw from 14-jun-2023 was found to be reactive in the elecsys hiv duo assay.The samples were further tested with the biorad new lav blot 1 and the inno-lia hiv i/ii score, where the sample from (b)(6) 2023 had an indeterminate and negative result and the sample from (b)(6) 2023 had both times an indeterminate result.Taking all results into account, the cause of the event was consistent with that the patient sample is very likely from an early seroconversion phase.The investigation did not identify a product problem.Per product labeling: "for diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination, and other findings." "a negative test result does not completely rule out the possibility of an infection with hiv.Serum or plasma samples from the very early phase (or the late phase) of hiv infection can occasionally yield negative findings.".
|